Next Article in Journal
Disruption of Cholinergic Circuits as an Area for Targeted Drug Treatment of Alzheimer’s Disease: In Vivo Assessment of Short-Term Plasticity in Rat Brain
Next Article in Special Issue
New Class of Efficient T2 Magnetic Resonance Imaging Contrast Agent: Carbon-Coated Paramagnetic Dysprosium Oxide Nanoparticles
Previous Article in Journal
A Novel Integrated Active Herbal Formulation Ameliorates Dry Eye Syndrome by Inhibiting Inflammation and Oxidative Stress and Enhancing Glycosylated Phosphoproteins in Rats
Previous Article in Special Issue
Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma
Open AccessArticle

A Photocleavable Contrast Agent for Light-Responsive MRI

1
Department of Radiology, Medical Imaging Center, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, The Netherlands
2
Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands
3
Department of Nuclear Medicine and Molecular Imaging, Medical Imaging Center, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713GZ Groningen, The Netherlands
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(10), 296; https://doi.org/10.3390/ph13100296
Received: 24 August 2020 / Revised: 18 September 2020 / Accepted: 3 October 2020 / Published: 8 October 2020
(This article belongs to the Special Issue Next Generation of MRI Agents)
Thanks to its innocuousness and high spatiotemporal resolution, light is used in several established and emerging applications in biomedicine. Among them is the modulation of magnetic resonance imaging (MRI) contrast agents’ relaxivity with the aim to increase the sensitivity, selectivity and amount of functional information obtained from this outstanding whole-body medical imaging technique. This approach requires the development of molecular contrast agents that show high relaxivity and strongly pronounced photo-responsiveness. To this end, we report here the design and synthesis of a light-activated MRI contrast agent, together with its evaluation using UV–vis spectroscopy, Fast Field Cycling (FFC) relaxometry and relaxometric measurements on clinical MRI scanners. The high relaxivity of the reported agent changes substantially upon irradiation with light, showing a 17% decrease in relaxivity at 0.23T upon irradiation with λ = 400 nm (violet) light for 60 min. On clinical MRI scanners (1.5T and 3.0T), irradiation leads to a decrease in relaxivity of 9% and 19% after 3 and 60 min, respectively. The molecular design presents an important blueprint for the development of light-activatable MRI contrast agents. View Full-Text
Keywords: magnetic resonance imaging; responsive MRI contrast agents; photoremovable protecting groups; relaxivity; light activation magnetic resonance imaging; responsive MRI contrast agents; photoremovable protecting groups; relaxivity; light activation
Show Figures

Graphical abstract

MDPI and ACS Style

Reeßing, F.; Huijsse, S.E.M.; Dierckx, R.A.J.O.; Feringa, B.L.; Borra, R.J.; Szymański, W. A Photocleavable Contrast Agent for Light-Responsive MRI. Pharmaceuticals 2020, 13, 296.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop